Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019075 | 0.81 | MAP4K4 (0.56) | DYRK1ADYRK1BPIK3CGADORA1EGFR | |
| SCHEMBL13019080 | 0.80 | APP (0.48) | APPPIK3CGQDPR | |
| SCHEMBL13019077 | 0.75 | PIK3CG (0.63) | APPPIK3CGADORA2AADORA1MAP4K4 | |
| SCHEMBL13019079 | 0.75 | DHFR (0.53) | APPPIK3CGMAP4K4 | |
| SCHEMBL17432782 | 0.68 | USP7 (0.63) | MAP4K4 | |
| SCHEMBL13019081 | 0.67 | ADORA2A (0.54) | DYRK1ADYRK1BCLK1CLK2DYRK2 | |
| SCHEMBL6701547 | 0.66 | PIK3CG (0.51) | DYRK1AAPPPIK3CGADORA2AADORA1 | |
| SCHEMBL17665854 | 0.66 | MAP4K4 (0.62) | MAP4K4 | |
| SCHEMBL17665805 | 0.66 | MAP4K4 (0.61) | MAP4K4 | |
| SCHEMBL338028 | 0.64 | APP (1.00) | APPQDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | RBP1, RBP4, VCAM1 | DYRK1A 4783/4885DYRK1B 4738/4885CLK1 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.